Sarepta settles REGENXBIO, UPenn patent litigation for USD 39 million
Bitget2026/09/23 20:14- Sarepta Therapeutics reached a settlement on Sept. 23, 2026 to resolve patent infringement litigation tied to AAVrh74-based gene therapies.
- Payment of USD 39 million due to REGENXBIO within 10 days; charge previously recorded for the quarter ended June 30, 2026.
- REGENXBIO and the University of Pennsylvania released claims through the effective date tied to certain AAVrh74-related patents.
- Non-suit commitments cover ELEVIDYS and other AAVrh74-based programs; REGENXBIO also agreed not to sue over patents covering existing ELEVIDYS.
- Cases to be dismissed with prejudice; no admission of liability; each party to cover its own legal costs.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Analysis: Wall Street Is Not Yet Ready to Short AI in Large Numbers
Overseas capital is aggressively buying US stocks! Net inflows reached $942 billions over the past 12 months, marking a record since 1985.
According to data from the US Department of the Treasury, in the 12 months ending July this year, overseas investors made net purchases of US stocks totaling $942 billion, marking the highest rolling 12-month total since records began in 1985. The net purchases in the second quarter alone reached $426 billion, setting a new single-quarter record. Meanwhile, overseas demand for US Treasuries has noticeably cooled, with purchase volumes falling significantly. As a result, the US is facing higher costs in government debt financing.
RootData: BIO will unlock tokens worth about $1 million in one week
Crypto prices
More
